Risk stratification of plasma cell neoplasm: Insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cig FISH) vs. conventional FISH

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 5, 2012, Pages 366-374

  Dong, Henry ^a   Yang, Hai Su ^a   Jagannath, Sundar ^c   Stephenson, Christine F ^b   Brenholz, Pauline ^a   Mazumder, Amitabha ^d   Chari, Ajai ^c  

^a Esoterix Genetic Laboratories LLC   (United States)

^b Esoterix Genetic Laboratories LLC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cIg FISH; Cytogenetic analysis; Myeloma; Plasma cell; Risk stratification

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CANCER RISK; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOPLASM; CYTOPLASMIC IMMUNOGLOBULIN FLUORESCENCE IN SITU HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA CELL; PLASMA CELL; PLASMACYTOMA; RELIABILITY; SENSITIVITY AND SPECIFICITY; STRATIFIED SAMPLE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; CYTOPLASM; FEMALE; HUMANS; IMMUNOGLOBULINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL; PLASMA CELLS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84867429795     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.05.003     Document Type: Article

References (49)

1. P.R. Greipp, J. San Miguel, B.G. Durie International staging system for multiple myeloma J Clin Oncol 23 2005 3412 3420
2. G.W. Dewald, T. Therneau, D. Larson Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma Blood 106 2005 3553 3558
3. H. Avet-Loiseau, M. Attal, P. Moreau Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome Blood 109 2007 3489 3495
4. K. Neben, A. Jauch, U. Bertsch Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the international staging system classification allows stratification of myeloma patients undergoing autologous stem cell transplantation Haematologica 95 2010 1150 1157
5. R. Fonseca, P.L. Bergsagel, J. Drach International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 23 2009 2210 2221
6. N.C. Munshi, K.C. Anderson, P.L. Bergsagel Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2 Blood 117 2011 4696 4700
7. J.F. San Miguel, R. Schlag, N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906 917
8. P. Kapoor, S. Kumar, R. Fonseca Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Blood 114 2009 518 521
9. D. Reece, K.W. Song, T. Fu Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Blood 114 2009 522 525
10. S.V. Rajkumar, S. Jacobus, N.S. Callander Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 2010 29 37
11. H. Avet-Loiseau, X. Leleu, M. Roussel Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J Clin Oncol 28 2010 4630 4634
12. N. Korde, S.Y. Kristinsson, O. Landgren Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies Blood 117 2011 5573 5581
13. H. Avet-Loiseau, J.Y. Li, T. Facon High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies Cancer Res 58 1998 5640 5645
14. M.J. Calasanz, J.C. Cigudosa, M.D. Odero Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations Genes Chromosomes Cancer 18 1997 84 93
15. S.V. Rajkumar, R. Fonseca, G.W. Dewald Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma Cancer Genet Cytogenet 113 1999 73 77
16. M. Flactif, M. Zandecki, J.L. Laï Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma Leukemia 9 1995 2109 2114
17. J.A. Pérez-Simón, R. García-Sanz, M.D. Tabernero Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes Blood 91 1998 3366 3371
18. H. Avet-Loiseau, C. Brigaudeau, N. Morineau High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization Genes Chromosomes Cancer 24 1999 9 15
19. R. Königsberg, N. Zojer, J. Ackermann Predictive role of interphase cytogenetics for survival of patients with multiple myeloma J Clin Oncol 18 2000 804 812
20. G.W. Dewald Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma Int J Hematol 76 Suppl 2 2002 65 74
21. A. Fiserová, R. Hájek, V. Holubová Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells Neoplasma 49 2002 300 306
22. F.W. Cremer, M. Kartal, D. Hose High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH Cancer Genet Cytogenet 161 2005 116 124
23. G.J. Ahmann, S.M. Jalal, A.L. Juneau A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies Cancer Genet Cytogenet 101 1998 7 11
24. R. Fonseca, M.M. Oken, D. Harrington Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy Leukemia 15 2001 981 986
25. H. Chang, S. Sloan, D. Li The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant Br J Haematol 125 2004 64 68
26. A.H. Bryce, R.P. Ketterling, M.A. Gertz Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica 94 2009 380 386
27. S. Jagannath, P.G. Richardson, P. Sonneveld Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Leukemia 21 2007 151 157
28. V. Sagaster, H. Ludwig, H. Kaufmann Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion Leukemia 21 2007 164 168
29. H. Chang, Y. Trieu, X. Qi Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma Leuk Res 31 2007 779 782
30. J.D. Shaughnessy, Y. Zhou, J. Haessler TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 Br J Haematol 147 2009 347 351
31. R. Fonseca, S.V. Rajkumar, G.J. Ahmann Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis Leuk Lymphoma 39 2000 391 395
32. D.P. Steensma, G.W. Dewald, J.M. Hodnefield Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res 27 2003 235 242
33. D. Trost, B. Hildebrandt, M. Beier Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia Cancer Genet Cytogenet 165 2006 51 63
34. N. Mauritzson, M. Albin, L. Rylander Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001 Leukemia 16 2002 2366 2378
35. B. Swolin, S. Rödjer, J. Westin Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature Ann Hematol 87 2008 467 474
36. R. Königsberg, J. Ackermann, H. Kaufmann Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance Leukemia 14 2000 1975 1979
37. R. Fonseca, R.J. Bailey, G.J. Ahmann Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 2002 1417 1424
38. H. Avet-Louseau, A. Daviet, S. Sauner Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13 Br J Haematol 111 2000 1116 1117
39. J. Shaughnessy, E. Tian, J. Sawyer High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH Blood 96 2000 1505 1511
40. P. Bernasconi, P.M. Cavigliano, M. Boni Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance Br J Haematol 118 2002 545 549
41. H. Avet-Loiseau, T. Facon, B. Grosbois Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood 99 2002 2185 2191
42. R. Fonseca, M.M. Oken, P.R. Greipp The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance Blood 98 2001 1271 1272
43. S. Jagannath, R.A. Kyle, A. Palumbo The current status and future of multiple myeloma in the clinic Clin Lymphoma Myeloma Leuk 10 2010 E1 E16
44. A.H. Bryce, R.P. Ketterling, M.A. Gertz A novel report of cig-FISH and cytogenetics in POEMS syndrome Am J Hematol 83 2008 840 841
45. H. Avet-Loiseau, T. Facon, A. Daviet 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma Intergroupe Francophone du Myélome Cancer Res 59 1999 4546 4550
46. J.D. Shaughnessy Jr, J. Haessler, F. van Rhee Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics Br J Haematol 137 2007 530 536
47. O. Decaux, L. Lodé, F. Magrangeas Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome J Clin Oncol 26 2008 4798 4805
48. C. Largo, B. Saéz, S. Alvarez Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations Haematologica 92 2007 795 802
49. H. Avet-Loiseau, C. Li, F. Magrangeas Prognostic significance of copy-number alterations in multiple myeloma J Clin Oncol 27 2009 4585 4590